Maravai LifeSciences Reports Third Quarter 2025 Financial Results

Organizational restructuring and operating cost reduction initiatives on track

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates.

Quarterly Results:

• Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million

“We exited the third quarter confident about the future of our business. Cygnus continues to perform well and TriLink, although lumpy by nature, shows strong funnel and order velocity. We expect TriLink to deliver double digit sequential revenue growth in the fourth quarter," said Bernd Brust, CEO, Maravai LifeSciences.

Brust continued, “The work we’ve done to reset, refocus, and strengthen the company positions us to deliver attractive financial results in the fourth quarter and 2026 while continuing to serve our customers with the same level of dedication we’ve had in the past."

Revenue Guidance for Full Year 2025

Revenue for the full year 2025 is expected to be approximately $185.0 million.

Maravai’s revenue guidance for the full year 2025 is based on current expectations and does not include revenue, if any, from high-volume CleanCap orders for commercial phase vaccine programs, or potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.

Third Quarter 2025 Financial Results by Reporting Segment

Revenue for the third quarter was $41.6 million, representing a 39.7% decrease over the same period in the prior year and was driven by the following:

• Nucleic Acid Production revenue was $25.4 million for the third quarter, representing a 52.9% decrease year-over-year. The revenue decrease was primarily driven by a lack of high-volume CleanCap orders for commercial phase vaccine programs. Excluding revenue from high-volume CleanCap, revenue was down 28.8% year-over-year due to large GMP orders in the third quarter of 2024 not recurring in the third quarter of 2025, and lower discovery revenue driven by a softer research and development funding and purchasing environment.
• Biologics Safety Testing revenue was $16.3 million for the third quarter, up 7.2% year-over-year. The revenue increase was driven by strength in nearly all product lines.

Net loss and Adjusted EBITDA (non-GAAP) were $(45.1) million and $(10.8) million, respectively, for the third quarter of 2025, compared to net loss and Adjusted EBITDA (non-GAAP) of $(172.5) million and $16.2 million, respectively, for the third quarter of 2024.

Nine Months Ended September 30, 2025 Financial Results by Reporting Segment

Revenue for the nine months ended September 30, 2025 was $135.9 million, representing a 32.9% decrease over the same period in the prior year and was driven by the following:

• Nucleic Acid Production revenue was $85.2 million for the nine months ended September 30, 2025, representing a 44.8% decrease year-over-year. The revenue decrease was primarily driven by a lack of high-volume CleanCap orders for commercial phase vaccine programs. Excluding revenue from high-volume CleanCap, revenue was down 17.2% year-over-year due to lower demand for discovery and GMP consumable products.
• Biologics Safety Testing revenue was $50.7 million for the nine months ended September 30, 2025, up 5.2% year-over-year. The revenue increase was driven primarily by strength in HCP qualification services and increased demand for MockV viral clearance kits.

Net loss and Adjusted EBITDA (non-GAAP) were $(167.7) million and $(31.7) million, respectively, for the nine months ended September 30, 2025, compared to net loss and Adjusted EBITDA (non-GAAP) of $(213.6) million and $37.0 million, respectively, for the same period in the prior year.

Conference Call and Webcast

Maravai’s management will host a conference call today at 2:00 p.m. PT/ 5:00 p.m. ET to discuss its financial results for the third quarter of 2025 and other business updates. To participate in the conference call by telephone, approximately 10 minutes before the call, dial (800) 579-2543 or (785) 424-1789 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com/.

Non-GAAP Financial Information

This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: Adjusted EBITDA and Adjusted fully diluted Earnings Per Share (EPS).

Maravai defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider representative of our ongoing operating performance including, as applicable: (i) fair value adjustments to acquisition contingent consideration; (ii) incremental costs incurred to execute and integrate completed acquisitions, and associated retention payments; (iii) non-cash expenses related to share-based compensation; (iv) expenses incurred for acquisitions that were pursued but not consummated (including legal, accounting and professional consulting services); (v) non-cash expense associated with adjustments to the carrying value of the indemnification asset recorded in connection with completed acquisitions; (vi) executive leadership transition costs; (vii) impairment charges; (viii) restructuring costs; (ix) severance payments; and (x) inventory step-up charges in connection with completed acquisitions. Maravai defines Adjusted Net Loss as tax-effected earnings before the adjustments described above, and the tax effects of those adjustments. Maravai defines Adjusted fully diluted EPS as Adjusted Net Loss divided by the diluted weighted average number of shares of Class A common stock outstanding for the applicable period, which assumes the proforma exchange of all outstanding units of Maravai Topco Holdings, LLC (paired with shares of Class B common stock) for shares of Class A common stock.

These non-GAAP measures are supplemental measures of operating performance that are not prepared in accordance with GAAP and do not represent, and should not be considered as, an alternative to net loss, as determined in accordance with GAAP.

Management uses these non-GAAP measures to understand and evaluate Maravai’s core operating performance and trends and to develop short-term and long-term operating plans. Management believes the measures facilitate comparison of Maravai’s operating performance on a consistent basis between periods and, when viewed in combination with its results prepared in accordance with GAAP, help provide a broader picture of factors and trends affecting Maravai’s results of operations.

These non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for analysis of Maravai’s results as reported under GAAP. Because of these limitations, they should not be considered as a replacement for net loss, as determined by GAAP, or as a measure of Maravai’s profitability. Management compensates for these limitations by relying primarily on Maravai’s GAAP results and using non-GAAP measures only for supplemental purposes. The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

Forward-looking Statements

This press release contains, and Maravai’s officers and representatives may from time-to-time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravai’s expected revenue performance for full year 2025; the future of Maravai’s business; TriLink’s strong customer funnel and order velocity; expectations that TriLink will achieve double digit sequential revenue growth in Q4 2025; Maravai’s ability to deliver attractive financial results in the fourth quarter of 2025 and in 2026; and Maravai’s ability to continue to deliver historical levels of customer service following Maravai’s cost reduction initiatives and organizational changes, constitute forward-looking statements and are identified by words like “believe,” “expect,” “see,” “project,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of Maravai’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of management’s control. Maravai’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause Maravai’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

• The level of Maravai’s customers’ spending on and demand for outsourced nucleic acid production and biologics safety testing products and services.
• The risk that Maravai does not realize the expected operational or financial benefits from its organizational changes.
• Maravai’s operating results are prone to significant fluctuation, which may make Maravai’s future operating results difficult to predict and could cause Maravai’s actual operating results to fall below expectations or any guidance Maravai may provide.
• Uncertainty regarding the extent and duration of Maravai’s revenue associated with high-volume sales of CleanCap® for commercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside our control.
• The impact of shifts in U.S. and foreign trade policy, including the imposition of tariffs, trade restrictions and retaliatory actions, on demand for Maravai’s products and services and Maravai’s customers’ ability to commit funds to purchase such products and services.
• Decreases in research and development funding caused by changes in U.S. public health policy and the spending priorities of the U.S. federal government.
• Unintended consequences from our recent organizational changes and workforce reduction.
• Use of Maravai’s products by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical outcomes, development of alternative therapies, or increased regulatory scrutiny of these modes of treatment and their financial cost on Maravai’s customers’ use of its products and services.
• Competition with life science, pharmaceutical and biotechnology companies who are substantially larger than Maravai and potentially capable of developing new approaches that could make Maravai’s products, services and technology obsolete.

Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com